Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)

Capivasertib is a pan-AKT inhibitor. Preclinical data indicate activity in metastatic castration-resistant prostate cancer (mCRPC) and synergism with docetaxel. PATIENTS AND METHODS: ProCAID was a placebo controlled randomized phase II trial in mCRPC. Patients received up to ten 21-day cycles of doc...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Clin Oncol
Huvudupphovsmän: Crabb, Simon J., Griffiths, Gareth, Marwood, Ellice, Dunkley, Denise, Downs, Nichola, Martin, Karen, Light, Michelle, Northey, Josh, Wilding, Sam, Whitehead, Amy, Shaw, Emily, Birtle, Alison J., Bahl, Amit, Elliott, Tony, Westbury, Charlotte, Sundar, Santhanam, Robinson, Angus, Jagdev, Satinder, Kumar, Satish, Rooney, Claire, Salinas-Souza, Carolina, Stephens, Christine, Khoo, Vincent, Jones, Robert J.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Clinical Oncology 2021
Ämnen:
ORIGINAL REPORTS
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078455/
https://ncbi.nlm.nih.gov/pubmed/33326257
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01576
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk